@author-1788515151757110
The "ChinaVenture Rankings" have been published for 19 consecutive years, recognized within the industry for their professionalism, authority, and rigor. They are widely regarded as a bellwether for China's equity investment sector and serve as a key reference for capital commitments from many large institutional LPs.
This study, the world's first Phase 3 clinical trial covering RSV-infected infants under six months of age, successfully fills the evidence gap for targeted treatment approaches in this high-risk population and provides critical evidence for building a comprehensive RSV disease management system.
The rankings prioritize technical capability and commercialization potential, offering a panoramic survey of China's systematic breakthroughs in AI technology.
Following Qiming Venture Partners' portfolio companies' milestone moments with you
As China's first independently developed gene therapy for hemophilia B, Xinjiuning® will offer patients a completely new treatment option, with the potential to free them from a lifetime of frequent intravenous injections and help them return to a life without constraints.
By leveraging QNX's foundational software, WeRide has not only enhanced the performance of its driver-assistance systems, but also advanced autonomous vehicles as a core component of smart cities — easing traffic congestion, reducing carbon emissions, and improving road safety.
The ranking reflects the influence of China's private equity market in the global investment industry.
The ultimate goal of AI for Science is to achieve an "AI Albert Einstein" — capable of discovering entirely new, unknown scientific laws. But before that ambitious vision becomes reality, a more practical target is to build an "AI Doraemon": a form of inclusive intelligence that can empower every industry and sector.
Beyond its homegrown efficiency advantages, China's biotech sector must also seize the opportunities presented by global collaborative clinical development in the years ahead — leveraging strengths across different regions worldwide to maximize biotech value creation.
